The catalogue
PT-141 doesn’t fit in one drawer.
PT-141 began with tanning research. Its approved use concerns desire. The paper trail explains how those stories meet—and where they part.
A card catalogue of desire, side effects and mistaken identity.
What is PT-141?
PT-141 is bremelanotide’s early research name. I picture a card being pulled from the tanning drawer and filed under sexual desire: the molecule grew out of melanotan-II research that took an unexpected turn when sexual effects appeared alongside the original interest in skin pigmentation.
That is a wonderfully untidy origin for a medicine. It also explains why the skin story never quite goes away. The bremelanotide label includes a warning about darkening skin and other tissue, a reminder of its tanning origins.
My judgement is that this history makes more sense than the catch-all reputation of a sex booster. It leaves room for one molecule to have a real benefit, a narrow approval and an inconvenient side effect.
What is PT-141 peptide?
The PT-141 peptide is a synthetic ring of seven amino acids, the small building units of proteins. It resembles a body signal called alpha-MSH; early work placed its action in central melanocortin pathways, pathways in the brain involved in sexual response. An agonist is simply a substance that activates a receptor, a cell’s receiving point for a signal.
I expected the chemical identity to settle the story. Instead it opens several drawers. Desire, erections, skin pigment and appetite are not interchangeable outcomes, even when melanocortin biology connects them. The research file establishes a mechanism worth investigating; the approved label establishes a particular medicine and use.
The approved entry has a very specific subject.
FDA approved bremelanotide on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. In ordinary terms, desire has fallen after previously being normal, the problem extends beyond a particular partner or situation, and it causes marked distress. The U.S. prescribing information sets out that indication.
The two pivotal trials found improvements in desire and desire-related distress compared with placebo. Those findings do not establish an approved use for men, postmenopausal women, erectile dysfunction or enhanced performance. I regard those boundaries as essential to judging the finding.
A familiar molecule, uncertain contents.
An FDA-approved bremelanotide product, a compounded prescription and material labelled for laboratory research can all carry the same molecule’s name. They are different entries. The FDA-approved bremelanotide product has that indication; compounded medicines are not FDA-approved, and research-labelled powder is not for human consumption.
The forensic study of black-market melanocortin products is a particularly sobering companion to a drug label. It documents unregulated material circulating outside pharmaceutical safeguards. A name on a container cannot establish identity, purity or concentration. The effects file puts that uncertainty beside the medicine’s known risks.
What does a video visit mean for prescription access?
Because PT-141's lead use is a sensitive sexual-health condition, the access question matters, and the literature has begun to address it. A 2020 review examined how telemedicine is used for sexual-medicine patients, describing remote-evaluation workflows and the access considerations that come with prescribing sexual-health therapies [8]. A 2025 cross-country study documented how widely telemedicine was adopted for sexual medicine across eight countries during the pandemic [15]. This site does not connect anyone to a prescriber and dispenses nothing; it summarizes that published context while keeping the FDA-approved product, compounded prescription care, and research-labelled powder distinct. For the reported upsides and downsides, see PT-141 benefits and the full PT-141 effects page.
What that literature describes in the abstract has concrete operators. One current example of remote prescription care is Promise Peptides (mypromise.com), where PT-141 (bremelanotide) is prescribed now; the clinician holding a U.S. license may withhold an order after assessing the individual. That service sees U.S. patients only, and the choices offered in a given state also depend on the treatment; a compounded prescription has no FDA approval. This example leaves the site’s role unchanged: no prescribing, dispensing, or connection to a clinician.
An unexpected origin
Tanning work, sexual response and the experiment that measured something else.
Follow the history →A benefit with boundaries
The women in the trials, the questions they answered and the modest group differences.
Read the trial results →The awkward entries
Nausea, blood pressure, pigment and the separate uncertainty of research powder.
Read the safety file →